Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity.

Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR.

Vaccine. 2006 Sep 29;24(40-41):6392-404. Epub 2006 Jun 21.

PMID:
16831498
2.

Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus.

Pletnev AG, Claire MS, Elkins R, Speicher J, Murphy BR, Chanock RM.

Virology. 2003 Sep 15;314(1):190-5.

3.

Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys.

Rumyantsev AA, Chanock RM, Murphy BR, Pletnev AG.

Vaccine. 2006 Jan 12;24(2):133-43. Epub 2005 Aug 9.

PMID:
16115704
4.

Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys.

Blaney JE Jr, Speicher J, Hanson CT, Sathe NS, Whitehead SS, Murphy BR, Pletnev AG.

Vaccine. 2008 Aug 5;26(33):4150-9. doi: 10.1016/j.vaccine.2008.05.075. Epub 2008 Jun 13.

5.

Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.

Hanley KA, Goddard LB, Gilmore LE, Scott TW, Speicher J, Murphy BR, Pletnev AG.

Vector Borne Zoonotic Dis. 2005 Spring;5(1):1-10.

PMID:
15815144
6.

West Nile virus/dengue type 4 virus chimeras that are reduced in neurovirulence and peripheral virulence without loss of immunogenicity or protective efficacy.

Pletnev AG, Putnak R, Speicher J, Wagar EJ, Vaughn DW.

Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3036-41. Erratum in: Proc Natl Acad Sci U S A 2002 May 14;99(10):7184.

7.

Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccine.

Maximova OA, Speicher JM, Skinner JR, Murphy BR, St Claire MC, Ragland DR, Herbert RL, Pare DR, Moore RM, Pletnev AG.

Vaccine. 2014 May 30;32(26):3187-97. doi: 10.1016/j.vaccine.2014.04.002. Epub 2014 Apr 13.

10.

Evaluation of molecular strategies to develop a live dengue vaccine.

Lai CJ, Bray M, Men R, Cahour A, Chen W, Kawano H, Tadano M, Hiramatsu K, Tokimatsu I, Pletnev A, Arakai S, Shameem G, Rinaudo M.

Clin Diagn Virol. 1998 Jul 15;10(2-3):173-9.

PMID:
9741643
11.
12.
13.

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, Monath TP.

J Virol. 2004 Nov;78(22):12497-507.

14.

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.

Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, Ratterree M, Arroyo J, Georgakopoulos K, Catalan J, Monath TP.

J Virol. 2000 Jun;74(12):5477-85.

16.
17.

Genetically modified, live attenuated dengue virus type 3 vaccine candidates.

Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2004 Dec;71(6):811-21.

PMID:
15642976
18.
19.

Comparative neuropathogenesis and neurovirulence of attenuated flaviviruses in nonhuman primates.

Maximova OA, Ward JM, Asher DM, St Claire M, Finneyfrock BW, Speicher JM, Murphy BR, Pletnev AG.

J Virol. 2008 Jun;82(11):5255-68. doi: 10.1128/JVI.00172-08. Epub 2008 Mar 19.

Supplemental Content

Support Center